We’ve tracked nearly $80 million in new commitments for cancer research so far this year. With funders keen to leverage limited resources for maximum impact, a majority of that giving has gone to underfunded forms of cancer and young investigators.
Using genomics to design far more precise and effective medical treatment plans has been called the “wave of the future.” Now, as breakthroughs increase, more funders are coming to the table to back biomedical research in this emerging field.
Boehringer Ingelheim and its BI Cares Foundation make a lot of grants in Connecticut, but also to researchers nationwide. What healthcare access, STEM, and research programs does this pharmaceutical giant back?
A $10 million gift from the Belford Family Trust will establish a specialized Spinal Cord Injury Center at Ohio State. It comes at a time when funding needs to keep up with growing promise of therapeutic breakthroughs.
Pancreatic cancer often has a grim prognosis, typically evading early detection, and is difficult to treat. Three foundations are determined to change that with research grants for early detection and treatment of the disease.
A common theme of Len Blavatnik’s giving is an eagerness to support promising areas of medical research. Still, his biggest gift yet—$200 million to Harvard Medical School—has raised the usual questions about big philanthropy.
As Alzheimer’s disease inflicts an ever-rising toll on aging populations in the U.S. and overseas, the race is on for research breakthroughs. The Rainwater Charitable Foundation recently announced a major new prize focused on a key protein.
Diagnostic errors are the most common cause of medical errors, causing an estimated 40,000 to 80,000 deaths per year. But there is little funding for research on this problem. The Gordon and Betty Moore Foundation is looking to change that.
No mere “skin problem,” psoriasis is an incurable autoimmune disease afflicting 125 million people worldwide, carrying social and psychological impacts, and even the potential to shorten lifespans. But money for research is hard to come by. Who’s helping?
More deep-pocketed funders are interested in the age-old quest to live forever, in one form or another. We dig into the interesting story of Terasem Movement Foundation, founded by tech couple Martine and Bina Rothblatt.
Funding for rare diseases rarely comes from foundations or billionaire donors. Instead, it mostly comes from the families and friends of people affected. Here’s an example of how a small community of donors can underwrite significant research.
It’s hard to overstate the importance of patient private funding in the battle against Parkinson’s. Grantmakers in it for the long haul have often been behind gains made against the disease, with such successes now coming at a faster clip.
Paul Allen, who died recently, exemplified the best of big philanthropy. He embraced risk taking and cared deeply, journeying to the outer frontiers of scientific knowledge and to the front lines of the world’s biggest challenges. IP editor David Callahan assesses his legacy.
Susan G. Komen recently announced grants of $26 million to fund 62 new research projects that address some of the most difficult breast cancer cases. After years of troubles, this important funder has bounced back in a big way.
Helmsley Charitable Trust and Chan Zuckerberg Initiative, two heavy hitters in health research, are partnering to better understand cells in our intestines, as part of a larger moonshot project to catalogue all human cells.
The Muscular Dystrophy Association is the leading funder taking on this disease. We look at its recent research grants—and where the battle against MD now stands after decades of research.
Despite being one of the leading killers of men, claiming nearly 30,000 lives a year, prostate cancer research is seriously underfunded. Two grantmakers are leading the charge, but they can’t do it alone.
It’s not often that we see funders pooling money to create a not-for-profit generic drug company. In fact, we’ve never seen it before. Which is why the creation of Civica Rx deserves a close look.
The Helmsley Charitable Trust continues to address key healthcare challenges faced by rural residents. We look at the latest big grant by this national funder working off the beaten trail on matters of life and death.
The British Heart Foundation hopes to change the future of cardiovascular medicine by offering a research award of nearly $40 million for a groundbreaking idea. It’s one of the largest grants ever offered for biomedical research.
Andrew J. Viterbi's philanthropy tends to be ambitious in terms of size and in scope. We dig into his recent $50 million gift to the University of California, San Diego, which, true to form, aims to cure blindness.
The foundation has pledged $10 million to Stanford Medicine for the training of graduate students in the biomedical sciences, increasing the pipeline of talented young researchers who might otherwise struggle.
We don't see many community foundations prioritize medical research, which is more typically funded by national foundations and major philanthropists. But the Rhode Island Foundation has been working to catalyze and guide donor activity in this space since 2008.
About 60,000 new cases of Parkinson’s disease are diagnosed every year in the U.S. alone. We take a look at what two top research funders are doing to combat this disease.
We're tracking a growing number of donors who've been emerging lately from health and biotech. Cappy Rothman, a pioneer in male reproductive health, is a case in point.
The Wellcome Trust has established a big new fund to back bold ideas that fall outside the realm of conventional life sciences funding. It’s just latest such move by research funders trying to shake things up.
Screen legend John Wayne passed away from cancer in 1979. His family has been working ever since to raise money for cancer research and treatment. We check in with Wayne’s granddaughter on how it’s going.
The Science Philanthropy Alliance released its third survey on private funding for basic science. Overall numbers are steady, and funding continues to be highly concentrated.
It takes extensive training and the right personality to both treat patients and conduct scientific research. There’s been growing concern about the dwindling supply of physicians who do both. This foundation is on the case.
Donors have been reluctant to fund cannabis research on an extensive scale. Recent developments, however, suggest this dynamic may soon change—with major upsides for universities.